Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. DAL
2. META
3. FRMI
4. NFLX
5. IONS
6. EQPT
7. SPY
8. PSA
9. BA
10. PEP

Go back to Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa

Verrica Pharmaceuticals (VRCA) PT Lowered to $13 at RBC Capital

August 15, 2024 6:16 AM EDT

RBC Capital analyst Daniel Busby lowered the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $13.00 (from $14.00) while maintaining a Outperform rating.

The analyst comments "VRCA's 2Q report shows steady progress for YCANTH through its molluscum contagiosum launch as distribution network expands; although aspects such as... More